Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Other Events
Item8.01
| Other Events |
On January20, 2017, Minerva Neurosciences, Inc. (the Company)
issued a press release providing additional details from the
Companys Phase IIb clinical trial of MIN-101. A copy of the above
referenced press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K. The Company is also filing as Exhibit 99.2 to
this Current Report on Form 8-K an updated slide to be used in
its Corporate Presentation.
| Item9.01. | Financial Statements and Exhibits |
(d)Exhibits
|
Exhibit No. |
Description |
|
| 99.1 | Press Release of the Company dated January20, 2017 | |
| 99.2 | Corporate Presentation slide |
About Minerva Neurosciences, Inc. (NASDAQ:NERV)
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein. Minerva Neurosciences, Inc. (NASDAQ:NERV) Recent Trading Information
Minerva Neurosciences, Inc. (NASDAQ:NERV) closed its last trading session 00.00 at 10.50 with 149,912 shares trading hands.
